Moxifloxacin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Moxifloxacin
- Molecular weight
- 401.44
- Structure (SMILES)
- COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
- avelox
- Avelox
- avelox i v
- Avelox i.v.
- 1 cyclopropyl 6 fluoro 1 4 dihydro 8 methoxy 7 4as 7as octahydro 6h pyrrolo 3 4 b pyridin 6 yl 4 oxo 3 quinolinecarboxylic acid
- 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-((4AS,7AS)-OCTAHYDRO-6H-PYRROLO(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID
- avelox iv
- Avelox iv
- moxifloxacin
- Moxifloxacin
- moxifloxacin [INN]
- MOXIFLOXACIN [MI]
- MOXIFLOXACIN [VANDF]
- Moxifloxacin [WHO-DD]
- moxifloxacin inn
- moxifloxacin mi
- moxifloxacin vandf
- moxifloxacin who dd
- moxifloxacine
- Moxifloxacine
- moxifloxacino
- Moxifloxacino
- zimoxin
- Zimoxin
- CAS registry numbers
- 151096-09-2
- ChEMBL ID
- CHEMBL32
- InChIKey
- FABPRXSRWADJSP-MEDUHNTESA-N
- RxNorm IDs (RxCUI)
- 139462
- FDA ingredient codes (UNII)
- U188XYD42P
- J01MA14
- S01AE07
Sources for recorded values
- 152946
- 40467042
- Applicant
- BAYER HLTHCARE
- Approval date
- 10 Dec 1999
- Application number
- NDA021085
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- moxifloxacin
- Type
- Synthetic organic
- Drug name stem
- -oxacin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Mechanism
- Bacterial DNA gyrase inhibitor
- Action type
- Inhibitor
- Target
- Bacterial DNA gyrase
- Mechanism
- Topoisomerase IV inhibitor
- Action type
- Inhibitor
- Target
- Topoisomerase IV
- Action type
- Inhibitor
- Gene symbol
- gyrA|gyrB
- Protein identifier
- P0AES4|P0AES6
- Organism
- Escherichia coli (strain K12)
- Action type
- Inhibitor
- Gene symbol
- parC|parE
- Protein identifier
- P0AFI2|P20083
- Organism
- Escherichia coli (strain K12)
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Heart Failure
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Epilepsy
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000474
- Subject identifier
- D004827
- Condition
- Hypertension
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Skin Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Coronary Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Abscess
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003030
- Subject identifier
- D000038
- Condition
- Cellulitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003035
- Subject identifier
- D002481
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003095
- Subject identifier
- D065626
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Lung Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Pain
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
And 56 more, listed on the interactive page.
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000373
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000474
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000540
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0001365
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003030
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003035
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003047
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004234
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004270
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 1
- Condition identifier
- EFO_0006505
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006911
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007149
And 75 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- musculoskeletal toxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- neurotoxicity
- Country
- United States
- Event
- anaphylactic reaction
- Reports
- 787
- Reporting signal score
- 1,494.8
- Event
- anaphylactic shock
- Reports
- 230
- Reporting signal score
- 362.357
- Event
- choroiditis
- Reports
- 42
- Reporting signal score
- 152.132
- Event
- contrast media allergy
- Reports
- 94
- Reporting signal score
- 321.899
- Event
- delirium
- Reports
- 168
- Reporting signal score
- 157.882
- Event
- dizziness
- Reports
- 686
- Reporting signal score
- 234.697
- Event
- drug hypersensitivity
- Reports
- 675
- Reporting signal score
- 428.078
- Event
- dyspnoea
- Reports
- 836
- Reporting signal score
- 304.691
- Event
- electrocardiogram qt prolonged
- Reports
- 293
- Reporting signal score
- 375.905
- Event
- erythema
- Reports
- 295
- Reporting signal score
- 131.674
- Event
- hypersensitivity
- Reports
- 668
- Reporting signal score
- 711.772
- Event
- iris transillumination defect
- Reports
- 46
- Reporting signal score
- 228.33
- Event
- mental disorder
- Reports
- 142
- Reporting signal score
- 173.637
- Event
- musculoskeletal injury
- Reports
- 35
- Reporting signal score
- 151.681
- Event
- palpitations
- Reports
- 234
- Reporting signal score
- 146.256
- Event
- paraesthesia
- Reports
- 279
- Reporting signal score
- 138.409
- Event
- pruritus
- Reports
- 580
- Reporting signal score
- 339.587
- Event
- rash
- Reports
- 1,034
- Reporting signal score
- 673.701
- Event
- swelling face
- Reports
- 193
- Reporting signal score
- 154.735
- Event
- tendon disorder
- Reports
- 68
- Reporting signal score
- 130.984
- Event
- tendon pain
- Reports
- 114
- Reporting signal score
- 288.743
- Event
- tendon rupture
- Reports
- 146
- Reporting signal score
- 288.12
- Event
- tendonitis
- Reports
- 217
- Reporting signal score
- 482.838
- Event
- torsade de pointes
- Reports
- 97
- Reporting signal score
- 140.149
- Event
- urticaria
- Reports
- 577
- Reporting signal score
- 510.558
And 1 more, listed on the interactive page.
- NCT00082173
- NCT00140309
- NCT00144417
- NCT00164463
- NCT00306319
- NCT00396084
- NCT00460759
- NCT00728507
- NCT00816426
- NCT01055145
- NCT01298336
- NCT01589497
- NCT01674218
- NCT01785186
- NCT01874314
- NCT02114684
- NCT02193776
- NCT02342886
- NCT02409290
- NCT02410772
- NCT02563327
- NCT05454345
- NCT05766267
- NCT00158093
- NCT04019652
And 148 more, listed on the interactive page.
- Dose
- 1 drop
- Route
- Topical ophthalmic
- How often
- 3 times a day
Conditions of use
- For 7 days
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 2
- Polar surface area
- 83.8
- Calculated partition coefficient (ALogP)
- 2.37
- Calculated partition coefficient (XLogP)
- 0.6
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 29
- Molecular formula
- C21H24FN3O4
- Monoisotopic mass
- 401.17508442
- Natural product
- No
- Recorded assays
- 5,026
- Active assays
- 222
- Confirmatory
- Screening
- Anti-Bacterial Agents
- Topoisomerase II Inhibitors
Distribution coefficient (LogD)
- Median
- -0.22
- Mean
- -0.623333
- Minimum
- -2.9
- Maximum
- 0.63
- Unit
- unitless
- Assays
- 6
- Standard deviation
- 1.29912
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Cardiac potassium channel inhibition
- Median
- 79,432.8
- Mean
- 79,432.8
- Minimum
- 79,432.8
- Maximum
- 79,432.8
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Solubility
- Median
- 777
- Mean
- 777
- Minimum
- 777
- Maximum
- 777
- Unit
- ug/mL
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Oral bioavailability
- Median
- 90
- Mean
- 89.5
- Minimum
- 86
- Maximum
- 92
- Unit
- %
- Assays
- 4
- Standard deviation
- 2.51661
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 31
- Mean
- 34.36
- Minimum
- 19
- Maximum
- 50
- Unit
- %
- Assays
- 5
- Standard deviation
- 13.9624
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (489)
- 4-way Crossover QT Evaluation in Healthy Subjects
- A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval
- A Cardiac Liability Study of Varegacestat in Healthy Participants
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)
- A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.
- A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
- A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections
- A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery
- A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval
- A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)
- A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
- A PAN-USR TB Multi-Center Trial
- A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects
- A Phase 1 QT Study in Healthy Male Subjects
- A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects
- A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
- A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
- A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
- A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
Approved for (2)
- Bacterial infectious disease
- Eye infectious disorder
In development for (70)
- Abscess Phase 3
- Acanthamoeba keratitis Phase 3
- Acute cholecystitis Phase 3
- Acute coronary syndrome Phase 1
- AIDS Phase 1
- Alzheimer disease Phase 1
- Amyotrophic lateral sclerosis Phase 1
- Anemia Phase 1
- Asthma Phase 1
- Bacterial conjunctivitis Phase 3
- Bacterial pneumonia Phase 3
- Breast cancer Phase 3
- Cancer Phase 2
- Cataract Phase 3
- Cellulitis Phase 3
- Cholangitis Phase 2
- Chronic bronchitis Phase 3
- Chronic obstructive pulmonary disease Phase 3
- Congestive heart failure Phase 1
- Constipation disorder Phase 1
Other linked conditions (4)
- Age-related macular degeneration
- Appendicitis
- Familial long QT syndrome
- Skin disease caused by bacterial infection